What’s new

• Bal Pharma added a promoter warrant proposal to its May 27 board agenda.
• The issue type is preferential, meaning insiders get first shot at equity.
• No size, price, or conversion terms have been disclosed yet.

Why it matters

For a ₹134-crore company, a promoter equity raise is a meaningful signal. Warrants carry an upfront premium and lock the promoter into future conversion. The missing detail is the price. At what discount to market would insiders get to buy in?

What we’re watching

• The strike price and warrant ratio when the board approves (or rejects) the plan.
• Any simultaneous pledge or lock-in announcement from the promoters.
• How the company plans to use the capital it raises.

The full read

Bal Pharma wants to raise cash from its own promoters. The Bangalore-based pharma company, with a market cap of ₹134 crore, has added a preferential warrant proposal to the agenda for its May 27 board meeting. The filing is an addendum to a prior notice, but the core event is new. Warrants let insiders lock in a price today for shares they convert later, bringing money in now without immediate dilution. What's missing is every number that matters: how many warrants, at what price, and what the promoters will pay upfront. For a nano-cap company, promoter commitment of any size is meaningful. The open question is the discount to market the insiders get.

Primary source: BSE · NSE